Afternoon trading July 29, page-245

Quarterlies out for BIT
REPORT ON ACTIVITIES FOR THE QUARTER ENDED 30 JUNE 2020
During the quarter ended 30 June 2020, Biotron Limited (‘Biotron’ or ‘the Company’) has achieved
outcomes including:
 Completion of chronic toxicology studies of BIT225 by a leading international contract
research organisation.
 Continuation of screening of Company compounds for activity against SARS-CoV-2, the
causative agent of Covid-19.
 Continuation of designing, synthesising and testing new compounds under its Hepatitis B
program.
 Presentation of new data on its lead anti-HIV-1 drug BIT225 at an international HIV-1
conference in July 2020.
 Appointment of a Chief Medical Officer to advise the Company on its HIV-1 development
program.


They say they are in a good financial position .